AskBio

Executive Summary

AskBio is a clinical-stage gene therapy company focused on developing adeno-associated virus (AAV) vector-based treatments for genetic and complex disorders. Founded in 2001 and headquartered in Research Triangle Park, North Carolina, the company has established a robust pipeline targeting diseases with high unmet need, including Pompe disease, Huntington's disease, and congestive heart failure. AskBio's lead product candidate, AB-100 (formerly ACT-101), is in Phase 2 development for Pompe disease, and the company is also advancing AB-1001 for Huntington's disease in Phase 1/2 trials. With a proprietary platform encompassing novel AAV capsids and manufacturing expertise, AskBio aims to address key limitations of gene therapy, such as immunogenicity and tissue targeting. The company's financial backing from parent entity Bayer AG provides stability, while its strong intellectual property portfolio supports long-term value creation. As a private entity, AskBio benefits from strategic flexibility, but its valuation and funding details remain undisclosed. The gene therapy field is competitive, with several players targeting similar indications, yet AskBio's differentiated capsid engineering and clinical progress position it as a notable contender. Near-term focus will be on generating pivotal clinical data and advancing pipeline assets toward registration.

Upcoming Catalysts (preview)

• Q4 2026Phase 2 Data Readout for AB-100 in Pompe Disease65% success
• Q1 2027Phase 1/2 Interim Results for AB-1001 in Huntington's Disease60% success
• Q3 2027Regulatory Filing for AB-100 in Pompe Disease50% success